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Objective: The study aimed to evaluate the long-term efficacy and safety of
vedolizumab in a real-life cohort of patients with inflammatory bowel diseases
enrolled at a tertiary referral center.
Methods: Data were retrospectively collected from August 2016 to November 2018.
The primary outcomes were clinical response and remission at 14, 24, and 52 weeks,
and steroid-free remission rate (SFRR) at 52 weeks. Endoscopic response and remis-
sion rates at 52 weeks were the secondary outcomes.
Results: Altogether 49 patients (22 with ulcerating colitis [UC] and 27 with Crohn’s
Disease [CD]) were enrolled. The clinical response rate gradually dropped from 85%
and 50% in CD and UC, respectively, at week 14 to 59% and 25% at week 52, with
significantly a higher response in CD at week 14. The endoscopic response at week
52 was 55% in CD and 25% in UC (P = 0.21). CD group had a higher SFRR than UC
group (41% vs 20%) at 52 weeks, although the difference was not statistically signifi-
cant. Similar clinical and endoscopic rates were observed in biologic-naive and
-experienced patients. We reported no discontinuation due to adverse drug reac-
tions, and only mild to moderate events.
Conclusions: In our cohort the clinical response in the induction phase was similar to
those of registered trials, despite surprising better results for CD. During the mainte-
nance phase we observed an higher drop out than in the reported literatures. Of
note, its good safety profile makes vedolizumab a reliable choice in patients with con-
traindications to anti-tumor necrosis factor agents.
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1 | INTRODUCTION
The control of inflammation in inflammatory bowel diseases (IBD),
both in patients with Crohn's disease (CD) and ulcerative colitis (UC),
has been a major topic of research in the last 20 years. The develop-
ment of specific anti-tumor necrosis factor (TNF) agents is considered
the first fundamental step in IBD management and this has allowed
the achievement of deep remission in a high proportion of patients.1
Unfortunately, 10%-30% of patients are primary non-responders to
anti-TNF and more than 50% of responders lose control over time.2
Therefore, new therapeutic agents with different targets of inflamma-
tion are deeply needed.3
Vedolizumab (VDZ) is a fully human immunoglobulin G1 monoclo-
nal antibody selective for the gut. It has specific action against leuko-
cyte gut homing, blocking the integrin α4β7 on circulating
lymphocytes and preventing their diapedesis through the endothelial
walls.4 Three registered trials (GEMINI) have demonstrated the effi-
cacy and safety of the molecule in patients who are naive or experi-
enced with anti-TNF.5-7 Long-term efficacy and safety up to 5 years
of follow-up of these cohorts have also been reported.8,9
Considering the highly selective character of trial enrollment, it is
always fundamental to observe whether real-life settings support the
initially reported results of a new drug.10 Real-world publications on
this field are accumulating, with some conflicting results,11-31 but only
a few of them include long-term evaluation at 1 year with endoscopic
assessment.20,27,31 Therefore, we presented an Italian single-center
study on VDZ long-standing effectiveness and tolerability in patients
with UC and CD at a tertiary referral setting.
2 | PATIENTS AND METHODS
Upon Institutional Review Board approval, the prospectively
maintained biologics database at the IBD Referral Center of the Flor-
ence University Hospital was retrospectively analyzed. From August
2016 to November 2018, two gastroenterologists with experiences in
the IBD field collected data for all adult (≥18 y) patients with IBD who
had started treatment with VDZ between July 2016 and July 2018 and
who had completed at least the induction regimen. All patients, except
one with IBD undefined (IBD-U), had an established diagnosis of UC or
CD according to the European evidence-based guidelines.32,33
2.1 | Medical workup
Clinical history of all the patients were collected and they underwent
physical examination before starting VDZ treatment. Furthermore,
routine screening for tuberculosis (both serology and chest radiogra-
phy), common viruses (Epstein-Barr virus, cytomegalovirus, varicella
zoster virus, human immunodeficiency virus, hepatitis B and C viruses)
and antinuclear antibodies was carried out, as recommended by the
guidelines.34
Clinical activity was classified according to the partial Mayo score
(PMS) for UC and the Harvey-Bradshaw index (HBI) for CD and
recorded at week 0, 14, 24, and 52.35,36 Endoscopic assessment was
classified according to the Mayo endoscopic subscore (MAYO) for
UC, the simple endoscopic score for Crohn's Disease (SES-CD) for
non-resected patients with CD, while the Rutgeerts score was used
for the CD group with prior surgery.37-39 These evaluations were per-
formed at baseline and at week 52 for patients with a clinical
response, and just before the ending point in patients without clinical
improvement. Patients' comorbidities were evaluated with the
Charlson comorbidity index (CCI).40
After having given their signed informed consents, patients were
administered with VDZ 300 mg (Entyvio; Takeda Pharmaceutical,
Tokyo, Japan) intravenously at week 0, 2 and 6, and then every
8 weeks. Patients with CD who had no clinical response to the induc-
tion regimen received an additional dose at week 10. Dose intensifica-
tion every 4 weeks was an option for patients with a partial loss of
response. The last follow-up was recorded in November 2018. For
patients who withdrew from VDZ, the date of the last follow-up visit
was set as the time point of discontinuation. All possible adverse drug
reactions were recorded.
2.2 | Study outcomes
The primary outcomes were clinical response and remission rates
at 14, 24, and 52 weeks, and steroid-free remission rate at 52 weeks.
A clinical response was defined as a PMS <4 or a reduction of at least
30% of activity for UC and IBD-U, and a HBI <7 or a reduction of at
least 3 points for CD. Clinical remission was defined as a PMS of 0-1
for UC and IBD-U, and an HBI <4 for CD. The steroid-free remission
rate was defined as clinical remission with no need for systemic
corticosteroids.
The secondary outcomes were endoscopic response and remis-
sion rates at 52 weeks, and the safety profile both in monotherapy
and in combination with immunosuppressants. Endoscopic response
was defined as a MAYO score of 0-1 for UC and IBD-U, and SES-CD
or a Rutgeerts score of <6 or i0-i1, respectively, for CD. Endoscopic
remission was defined as MAYO score of 0 for UC and IBD-U, and
SES-CD or Rutgeerts score, respectively, of 0-2 or i0 for CD. Among
biochemical markers, only C-reactive protein (CRP) was evaluated.
2.3 | Statistical analysis
Two major groups of UC (including the patient with IBD-U) and CD
cohorts were enrolled for data collection and analysis. We took into
account the following variables to test the heterogeneity of the two
groups: sex, age at diagnosis and disease duration, age at administra-
tion of VDZ, CCI, disease duration, extra-intestinal manifestations,
baseline clinical or endoscopic activity, baseline CRP level, previous
anti-TNF exposure, and concomitant combination therapies.
Descriptive data were obtained for the groups reporting median
and interquartile range (IQR) for continuous variables, while numbers
and frequencies or proportions were used for categorical variables.
Comparisons between categorical variables were performed with the
χ2 test or Fisher's exact test for small samples; and comparisons
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TABLE 1 Baseline characteristics of patient cohorts
Sex (n, %) UC (n = 22) CD (n = 27) P value
Male 9 (41) 19 (70) 0.07
Female 13 (59) 8 (30)
Age at diagnosis (y) (median, IQR) 49.5 (29-59.5) 25 (16-37) 0.006
Age at VDZ administration (y) (median, IQR) 58 (38-68) 44 (30-69) 0.19
Disease duration (y) (median, IQR) 8 (4.5-13.5) 15 (8-27) 0.01
Charlson comorbidity index (n, %)
0 7 (32) 11 (41) 0.73
≥1 15 (68) 16 (59)
Montreal classification for CD (n, %)
Age at diagnosis (y)
A1 (≤16) 7 (26)
A2 (17-40) 15 (55)
A3 (>40) 5 (19)
Location
L1 (ileal) 6 (22)
L2 (colonic) 1 (4)
L3 (ileocolonic) 18 (67)
L4 (isolated upper disease)a 4 (15)
Behavior
B1 (non-stricturing, non-penetrating) 5 (19)
B2 (stricturing) 13 (48)
B3 (penetrating) 9 (33)
P (perianal disease) 10 (37)
Montreal classification for ulcerative colitis (n, %)
E1 (proctitis) 1 (5)
E2 (distal colitis) 10 (45)
E3 (pancolitis) 11 (50)
Extra-intestinal manifestations (n, %)
Yes 8 (36) 14 (52) 0.42
No 14 (64) 13 (48)
Basal endoscopic activity (MAYO and SES-CD) (n, %)
Severe 17 (77) 15 (55) 0.2
Non severe 5 (23) 12 (45)
Basal clinical activity
Severe 20 (91) 25 (93) 1
Non severe 2 (9) 2 (7)
Basal CRP (ULN 0.5 mg/dL) (median, IQR) 0.52 (0.30-1.95) 0.8 (0.3-2) 0.5
Corticosteroids during therapy (n, %)
Yes 17 (77) 15 (56) 0.14
No 5 (23) 12 (44)
Previous administration of anti-TNF (n, %)
No 9 (41) 6 (22) 0.27
Yes 13 (59) 21 (78)
• 1 Biologic 4 (18) 7 (26) n.a.
• 2 Biologics 5 (23) 11 (44)
• 3 Biologics 3 (14) 3 (11)
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between continuous variables were assessed with the Mann-Whitney
U test. The long-term clinical effectiveness of VDZ beyond the first
52 weeks of treatment was evaluated with the Kaplan-Meier method.
GraphPad Prism version 8 (GraphPad Software, San Diego, CA,
USA) was used to carry out statistical analyses. The presence of a sta-
tistical significance for P was set at < 0.05.
3 | RESULTS
3.1 | Study population
In total, 49 patients received VDZ during the study period: 21 with
UC and one with IBD-U whom we considered together as in the UC
group for all analyses, and 27 with CD. Table 1 shows the base char-
acteristics of the groups. The CD and UC groups were homogeneous
except for their age at diagnosis (younger in CD, P = 0.006) and dis-
ease duration (longer for CD, P = 0.01). An additional dose at week
10 was given in 14 (52%) patients with CD. Dose intensification was
attempted in 15 (31%) of all patients, with clinical benefit to six (40%)
of them.
3.2 | Clinical and endoscopic outcomes
The main end-point results of the study are summarized in Table 2. At
14-week follow-up, clinical response was achieved by 23 (85%)
patients with CD and 11 (50%) patients with UC, with a statistically
significant better outcome in CD (P = 0.01); 18 (67%) patients with
CD and 7 (32%) with UC were considered as being in clinical remis-
sion at the same time point (P = 0.03). Three patients with experience
of anti-TNF (two with UC and one with CD) discontinued treatment
before the end of induction regimen because of an inadequate
response to severe disease and underwent surgery. At week 24, 23
TABLE 1 (Continued)
Sex (n, %) UC (n = 22) CD (n = 27) P value
COMBO (VDZ + IMS) (n, %)
Yes 9 (41) 7 (26) 0.42
No 13 (59) 20 (74)
aL4 can be added to L1-L3 when concomitant upper gastrointestinal disease is present.
Abbreviations: CD, Crohn’s disease; CRP, C-reactive protein; IMS, immunosuppressants; IQR, interquartile range; MAYO, Mayo endoscopic subscore; n.a.,
not applicable; SES-CD, simple endoscopic score for Crohn's Disease; TNF, tumor necrosis factor; UC, ulcerative colitis; ULN, upper limit of normal; VDZ,
vedolizumab.
TABLE 2 Response and remission rates at 14, 24, and 52 wks
(n, %)
UC
N = 22
CD
N = 27
P
value
Clinical response at 14 wks 11/22 (50) 23/27 (85) 0.01
Clinical remission at 14 wks 7/22 (32) 18/27 (67) 0.02
Clinical response at 24 wks 13/22 (59) 23/27 (85) 0.055
Clinical remission at 24 wks 7/22 (32) 16/27 (59) 0.04
Clinical response at 52 wksa 5/20 (25) 13/22 (59) 0.06
Clinical remission at 52 wksa 4/20 (20) 10/22 (45) 0.11
Endoscopic response at
52 wksa
5/20 (25) 12/22 (55) 0.21
Endoscopic remission at
52 wksa
4/20 (20) 6/22 (27) 0.72
Bold font indicates P < 0.05.
aData at 52 wks were considered including patients still on treatment at
that time point or patients who dropped out; patients with fewer than
52 weeks of observation but still on treatment were excluded.
Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis.
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F IGURE 1 Clinical and endoscopic
outcomes at the three time points: 14,
24, and 52 weeks. No statistically
significant difference was found
between the two groups of biologic-
naive and biologic-experienced
patients [Color figure can be viewed at
wileyonlinelibrary.com]
238 DRAGONI ET AL.
(85%) patients with CD and 13 (59%) with UC had a clinical response
(P > 0.05); 16 (59%) patients with CD and 7 (32%) with UC achieved
clinical remission (P = 0.04). At this observation point, two other
patients prematurely stopped treatment due to loss of response.
At 52 weeks, seven patients had received VDZ for less than the
selected time point, thus, they were excluded from data analysis and
we considered only the patients who had undergone at least
52 weeks of treatment or who dropped out before reaching the time
point because of inefficacy or adverse drug reactions. Therefore, 13
(59%) patients with CD and 5 (25%) with UC had a clinical response
and 10 (45%) with CD and 4 (20%) with UC had clinical remission. An
endoscopic response was found in 12 (54%) CD patients and 5 (25%)
patients with UC, endoscopic remission in 6 (27%) with CD and 4
(20%) with UC. No statistical difference was noted between the two
cohorts at this time point, either for clinical or for endoscopic out-
comes. All patients with an endoscopic response were still receiving
treatment at the end of the study (up to 28 mo). Median treatment
duration was 52 weeks (IQR 36-64 weeks) in the overall cohort, and
76 weeks (IQR 56-88 weeks) in patients who continued VDZ for over
12 months. No statistically significant difference in terms of clinical
and endoscopic outcomes was demonstrated between patients with
previous exposure to anti-TNF drugs and naive patients, despite a
trend of better responses in the naive group (Figure 1).
The CD and UC groups did not differ in terms of a steroid-free
remission rate at 52 weeks, which was 41% (9/22) in those with CD
and 20% (4/20) in those with UC (P = 0.19). CRP gradually decreased
in patients with CD and UC, with a drop of 0.51 mg/dL from baseline
to 9 months. A lower baseline CRP was also a good response predic-
tor at week 14 (P = 0.02).
3.3 | Safety profile
Mild to moderate adverse drug reactions were reported in 47%
(23/49) of patients and none of them discontinued VDZ due to
adverse drug reactions. The most frequent adverse drug reactions
were upper respiratory (n = 13) and urinary (n = 4) infections; no safety
concerns were reported. Concomitant therapies (immunosuppressants
and corticosteroids) did not influence the adverse drug reaction rates.
3.4 | Drug continuation
Patients still on treatment after 52 weeks were followed up over time
and data were collected and inserted in a Kaplan-Meier survival curve
analysis. We reported comparable long-term drug survival in the two
CD and UC groups (P = 0.08, Figure 2). At 52 weeks, the overall prob-
ability of continuing VDZ treatment was 54% (39% for UC, 67% for
CD), while at 104 weeks was 30% (20% for UC, 37% for CD).
4 | DISCUSSION
Real-world data on VDZ effectiveness and tolerability have started to
accumulate in the last 2 years. Our single-center data collection is the
third evaluation after that of Kotze et al27 and the VICTORY Consor-
tium studies20,31 to analyze both a long-term follow-up of at least
1 year and routine endoscopic assessment.
The GEMINI randomized clinical trial published in 20135,7 led to
the approval of VDZ for the treatment of patients with CD and UC,
including both participants who were naive to anti-TNF agents and
those who had experience of them. However, in this context of highly
selective context it was to compare their findings with those of subse-
quent observational series. Therefore, it is prudent to discuss our data
in the light of other real-life scenarios results.
In our analysis, VDZ was surprisingly found to induce a faster clini-
cal remission in CD than in UC. The same results were shown by
Kopylov et al12 with similar rates of response and remission both for
CD and UC. Other authors17,18,23,28 found no difference in CD and
UC cohorts after the induction phase, while in one study a higher clin-
ical benefit in patients with UC29 was seen, with a cumulative clinical
remission plus response rate after 14 weeks of 91.2% in UC and
78.5% in CD (P = 0.02). Again, at 52 weeks the trend of the response
in our study was favorable to CD patients despite a lack of statistical
significance; in other real-life studies, the two groups were compara-
ble15 or there were higher response rates in UC.27,29,30 In addition,
despite the better clinical results in CD, our endoscopic remissions at
52 weeks (15% UC and 27% CD) were very low compared with the
other available data (41% of UC and 63% of CD in the VICTORY
studies20,31 and 25.9% of CD and 47.8% of UC patients in a large
Canadian cohort27). A possible explanation for these findings may be
the high percentage of patients with severe disease and patients with
anti-TNF experience at baseline in our cohort.
As regards the steroid-free remission rate, our rates (41% CD and
20% UC) were similar to those of the VICTORY studies (34% CD and
37% UC) and higher than the one reported by Stallmach et al (15% for
CD and 22% for UC).15 With respect to adverse drug reactions, the
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F IGURE 2 Kaplan-Meier survival curve analysis comparing the
long-term clinical efficacy of vedolizumab in patients with
ulcerative colitis and Crohn’s disease (CD). Despite a trend
towards higher efficacy in CD, no statistically significant difference
was found (P = 0.08) [Color figure can be viewed at
wileyonlinelibrary.com]
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safety profile in our cohort was comparable to that described both in
registrational trials and in other populations.41
Our Kaplan-Meier survival analysis reported lower response rates at
1 and 2 years than Kotze et al27 (56% vs 70% at 52 weeks, 30% vs 53.2%
at 104 wks), showing that the trend of sustained remission in patients
with initial response is not to be expected in all clinical scenarios. In this
regard, the perfect timing for defining a primary response or non-response
to VDZ is currently unknown, as its effect may be slower than what is
common in an anti-TNF response.42 Therefore, it appears advisable to
wait for at least 14 weeks or more before discontinuation due to non-
response; in fact, in our setting the earlier discontinuation of treatment
occurred only in patients who had to be urgently referred to surgery.
Some studies have shown better treatment outcomes in biologic-
naive patients.6,31,43 In our analysis, being naive or experienced with
anti-TNF was not a significant predictor of response, and this has also
been reported in other real-life settings.17,28
Recently, a score to predict VDZ response in patients with CD has
been developed and the cohort from the VICTORY study has been
used to validate the predictive score.44 Unluckily, baseline albumin
was not available for most of our patients and the prediction score
could not be used to explain the unexpectedly good clinical end-
points in our CD cohort.
The strong points of our study are the long period of evaluation
and the routine endoscopic assessment that were available for all
patients reaching 52 weeks of treatment or dropping out of the study.
Most of the other real-world settings have the drawback of limited or
no endoscopic results. Our study also had some limitations. First, it
had a retrospective setting and this could have led to possible biases.
For example, in the estimation of clinical and endoscopic activity, we
partially overcame this problem by using standardized spreadsheets
for clinical assessment and the agreement of two expert endoscopists
for the endoscopic scores. Second, despite our detailed questionnaire,
minor adverse events and infections might have been omitted by
patients, resulting in a possible underestimation compared with clini-
cal trials. Moreover, at the time of our analysis it was not possible to
measure the VDZ trough level; consequently, dose intensification was
based only on its clinical efficacy. In the future, the possibility of ther-
apeutic drug monitoring will help the optimization of treatment and
the more precise management of a loss of response.45
The place of VDZ in the biologic treatment algorithm is still
debated and should be personalized. In fact, VDZ is to be preferred in
patients who have positive history of opportunistic or serious infec-
tions, past malignancy, and elderly patients due to its attractive safety
profile.46 A study has suggested a combination therapy of VDZ with
anti-TNF, reporting no additional safety signals than that of single
therapies on their own.47 Head-to-head trials versus anti-TNF agents
are required to compare their safety and effectiveness.
5 | CONCLUSION
In conclusion, our study reported a high rate of clinical response in both
the patients with UC and those with CD during the induction phase, as
well as surprising better results in CD than in patients with UC. During
the subsequent months of follow-up, our data found a higher drop out
than the reported in the literatures, probably due to more severe dis-
ease at the baseline and an elevated percentage of biologic-experienced
patients. As regards the safety profile, VDZ has been confirmed as a
well-tolerated biologic that should be considered as a reliable first
choice in patients with contraindication to anti-TNF agents.
In our center we believe it is very important to continue the
follow-up of the patients still on treatment after 52 weeks to improve
our understanding of the long-term efficacy and safety profile of
VDZ. An additional systematic review and meta-analysis of the avail-
able data is required studying the clinical and endoscopic efficacy of
VDZ at 1 year and beyond.
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